Cases
Representative Matters: Represented Glycoregimmune, Inc. in its $4.4 million equity financing transaction (April 2015). Represented Allele Biotechnology & Pharmaceuticals, Inc. in its license agreement with Ocata Therapeutics, Inc. for Allele's proprietary technology for generating human induced pluripotent stem cells (iPSCs). (March 2015). Represented Aurigene Discovery Technologies Limited in its collaboration, license
option agreement with Curis, Inc. for immuno-oncology
selected precision oncology targets (January 2015). Represented Aurigene Discovery Technologies Limited in its collaborative license, development
commercialization agreement with Pierre Fabre Pharmaceuticals for worldwide rights (excluding India) to AUNP12, an immune checkpoint modulator targeting the PD-1 pathway (February 2014). Represented Quest Diagnostics in the sale to Royalty Pharma of royalty rights from commercialization of the drug c
idate ibrutinib for $485 million (July 2013). Represented Micro-Imaging Solutions in its license agreement with Fujikura Ltd to jointly co-market nano-sized, complementary metal-oxide semiconductor, or CMOS, based endoscopes (May 2013). Represented NovaBay Pharmaceuticals, Inc. in its collaboration
license agreement with Virbac for exclusive worldwide rights to NovaBay's proprietary compound, auriclosene (NVC-422), for global veterinary markets (May 2013). Represented Kindstar Diagnostics Co. Ltd. in agreements to obtain rights to various diagnostic tests
technology in China, including agreements with Illumina, Mayo Medical Laboratories, BG Medicine, Pathwork Diagnostics, TessArae, BioView
Singulex (June 2011-May 2013). Represented Soligenix, Inc. in its collaboration with Intrexon to develop
commercialize human monoclonal antibody therapies for new biodefense
infectious disease applications for Melioidosis (May 2013). Represented Apricus Biosciences, Inc. in its sale of Totect (dexrazoxane HCl), a marketed injectable treatment for anthracycline extravasation, to Biocodex USA (April 2013). Represented Intelligent Medical Devices, Inc. (IMDx) in connection with its development
license agreement with Qiagen to design, develop
manufacture several undisclosed CE-marked
FDA cleared diagnostic tests for use on Qiagen's flagship QIAsymphony RGQ automated platform (January 2013). Represented Apricus Biosciences, Inc. in connection with its co-promotion agreement, asset-purchase agreement
assignment agreement with PediatRx relating to the pharmaceutical products Granisol
Aquoral (February 2012). Represented Santarus, Inc. in connection with its commercialization agreement with Depomed, Inc. to exp
Santarus' commercial, manufacturing
regulatory responsibilities for GLUMETZA (August 2011). Represented Intelligent Medical Devices, Inc. (IMDx) in connection with its agreement with Abbott Laboratories for the design, development
manufacture by IMDx of molecular diagnostic tests to be distributed by Abbott worldwide (January 2011). Represented NexMed (U.S.A.), Inc., a wholly owned subsidiary of Apricus Biosciences, Inc., in connection with its license agreement with Ellis Pharmaceuticals for the commercialization of NexMed's Vitaros product in the Gulf countries
part of the Middle East (January 2011). Represented NexMed (U.S.A.), Inc., a wholly owned subsidiary of Apricus Biosciences, Inc., in connection with its license agreement with Bracco SpA for the commercialization of NexMed's Vitaros product in Italy (December 2010).
